<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1425">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897464</url>
  </required_header>
  <id_info>
    <org_study_id>BT-AD-01</org_study_id>
    <nct_id>NCT04897464</nct_id>
  </id_info>
  <brief_title>Validation Study of a New Digital Treatment Test</brief_title>
  <official_title>Validation Study of a New Digital Treatment Test Based on Interactive Video Games for Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braingaze</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braingaze</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oculomotor behavior and cognitive processing of visual information are intimately connected.&#xD;
      AD patients show ocular movement problems. Oculomotor deficits are broad consisting mainly of&#xD;
      different saccade metrics, altered pupil responses. and smaller and irregular eye vergence&#xD;
      movements. Here we test an interactive eye-tracking game to improve eye motion control and&#xD;
      thereby training cognitive behavior&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MoCA</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>Measure changes in MoCA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MMSE</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>Measure changes in MMSE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CANTAB</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>Measure changes in CANTAB tests</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>MCI</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BGaze therapy Alzheimer</intervention_name>
    <description>BGaze Therapy is an interactive eye tracking game</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) Clinical diagnosis of MCI or AD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe cognitive deterioration&#xD;
&#xD;
          2. History of neurological disease with clinically relevant impact on cognition&#xD;
&#xD;
          3. Severe psychiatric disorder&#xD;
&#xD;
          4. Incidental structural brain findings with impact on cognitive impairment&#xD;
&#xD;
          5. Presence of relevant visual problems&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hans Super</last_name>
    <phone>0034931696572</phone>
    <email>hans@braingaze.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laszlo Bax</last_name>
    <phone>0034931696572</phone>
    <email>Laszlo@braingaze.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Braingaze</name>
      <address>
        <city>Matar√≥</city>
        <state>Barcelona</state>
        <zip>08302</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Super</last_name>
      <email>hans@braingaze.eu</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>anonymized data can be shared upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

